Evidence map›Paper›PMID 42583568›Full record

ArticleJournal of thoracic disease2026

Efficacy and safety of TQC3403 in patients with chronic obstructive pulmonary disease (COPD): a multicenter, randomized, open-label, phase 3 equivalence trial.

Dandan Chen, Kai Yang, Xunchao Liu, Qiang Zhang, Lingfeng Min, Junzheng Gao, Yan Wang, Haiping Liu, Weiguo Li, Lai Wei and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Dandan Chen *Department of Pulmonary and Critical Care Medicine, Shenzhen Key Laboratory of Respiratory Diseases, Shenzhen Clinical Research Center for Respiratory Disease, Shenzhen Institute of Respiratory Diseases, Shenzhen People's Hospital (the First Affiliated Hospital, Southern University of Science and Technology, the Second Clinical Medical College, Jinan University), Shenzhen, China.
Kai Yang *Department of Pulmonary and Critical Care Medicine, Shenzhen Key Laboratory of Respiratory Diseases, Shenzhen Clinical Research Center for Respiratory Disease, Shenzhen Institute of Respiratory Diseases, Shenzhen People's Hospital (the First Affiliated Hospital, Southern University of Science and Technology, the Second Clinical Medical College, Jinan University), Shenzhen, China.ORCID https://orcid.org/0000-0002-1982-4398
Xunchao LiuDepartment of Pulmonary and Critical Care Medicine, Heze Municipal Hospital, Heze, China.
Qiang ZhangDepartment of Pulmonary and Critical Care Medicine, the Affiliated Jiangyin Hospital of Nanjing University of Chinese Medicine, Jiangyin, China.
Lingfeng MinDepartment of Pulmonary and Critical Care Medicine, Subei People's Hospital of Yangzhou University, Yangzhou, China.
Junzheng GaoDepartment of Pulmonary and Critical Care Medicine, the Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.
Yan WangDepartment of Pulmonary and Critical Care Medicine, Liaocheng People's Hospital, Liaocheng, China.
Haiping LiuDepartment of Pulmonary and Critical Care Medicine, Shenzhen Key Laboratory of Respiratory Diseases, Shenzhen Clinical Research Center for Respiratory Disease, Shenzhen Institute of Respiratory Diseases, Shenzhen People's Hospital (the First Affiliated Hospital, Southern University of Science and Technology, the Second Clinical Medical College, Jinan University), Shenzhen, China.
Weiguo LiDepartment of Clinical Research Center, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Nanjing, China.
Lai WeiBiostatistics Department of Clinical Center of Research Institute, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Nanjing, China.
Ding YuDepartment of Clinical Research Center, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Nanjing, China.
Rongchang ChenDepartment of Pulmonary and Critical Care Medicine, Shenzhen Key Laboratory of Respiratory Diseases, Shenzhen Clinical Research Center for Respiratory Disease, Shenzhen Institute of Respiratory Diseases, Shenzhen People's Hospital (the First Affiliated Hospital, Southern University of Science and Technology, the Second Clinical Medical College, Jinan University), Shenzhen, China.ORCID https://orcid.org/0009-0003-3377-1872

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Although dual bronchodilators represent the cornerstone of pharmacological therapy for chronic obstructive pulmonary disease (COPD), few affordable generic products are available worldwide. This study aimed to evaluate the clinical equivalence between TQC3403 [the first generic umeclidinium/vilanterol (UMEC/VI) dry powder inhaler (DPI)] and ANORO Methods: This multicenter, randomized, open-label, phase 3 equivalence trial was conducted at 56 centers in China. Eligible patients with moderate-to-severe COPD were randomized in a 1:1 ratio to receive either TQC3403 or ANORO Results: A total of 414 patients were enrolled, with 207 in each group. Baseline demographic and clinical characteristics of the two groups were similar. The LSM difference in the change in trough FEV Conclusions: TQC3403 demonstrated clinical equivalence to ANORO Trial registration: The clinical research was registered at Chinese Clinical Trial Register (Ref: ChiCTR2600120078).

Indexed as

Chronic obstructive pulmonary disease (COPD)clinical equivalencedual bronchodilatorgeneric drugspirometry

Identifiers

PMID42583568
PMCPMC13460180

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.